Drugs / Branched-Chain Amino Acids
Branched-Chain Amino Acids
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT07412054 | Mar 2026 → Jun 2027 expected | hepatocellular carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT01860404 | Jan 2014 → Jan 2023 | traumatic brain injury | Children's Hospital of Philadelphia | Completed | Missed primary |
| Phase not applicable5 trials · 1 met primary | ||||||
| — | NCT06376266 | Oct → Dec 2023 | muscular atrophy | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT04243148 | May 2020 → Jun 2022 | cirrhosis of liver, muscular atrophy | Sant Pau Research Institute | Completed | Met primary |
| — | NCT03448848 | Mar 2018 → Aug 2020 | — | National Hepatology & Tropical Medicine Research Institute | Completed | No outcome recorded |
| — | NCT01773538 | Jan 2013 → Oct 2015 | cirrhosis of liver, hepatic encephalopathy | Mette Munk Lauridsen | Completed | No outcome recorded |
| — | NCT01687361 | Jun 2012 → Jun 2013 | — | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT01115686 Comparator | Jun 2010 → Jun 2012 | sleep apnea syndrome | University Hospital, Limoges | Withdrawn | No outcome recorded |
| — | NCT06483737 Background | Jun 2025 → Jun 2027 expected | hepatic encephalopathy | General Hospital of Shenyang Military Region | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | branched-chain amino acids | “The intervention group will receive a daily supplement of branched-chain amino acids combined with medium-chain triglycerides, while the control group will be given...” NCT06376266 ↗8“Several animal studies have shown that Branched-chain amino acids (BCAAs) may prevent acute liver injury” PMID 40537743 ↗ Jun 2025 “branched-chain amino acids (BCAA) supplementation” NCT01687361 ↗ “Branched Chain amino acids” NCT01773538 ↗ |
| Known as | BCAA | “Branched-chain amino acids (BCAA): In addition to the exercise program and the probiotic, patients in the intervention group will receive BCAA supplements” NCT04243148 ↗2“lactulose, rifaximin and branched chain amino acids (BCAA) or placebo lactulose, rifaximin and BCAA.” NCT01773538 ↗ “branched-chain amino acids (BCAA) supplementation” NCT01687361 ↗ |
| Known as | BCAAs | “This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAA's) in the treatment of concussion.” NCT01860404 ↗1“Several animal studies have shown that Branched-chain amino acids (BCAAs) may prevent acute liver injury” PMID 40537743 ↗ Jun 2025 |
| Known as | Bramino | “30 grams of branched chain amino acids (Bramino) per day is given to the patients in the antiHE treatment arm along with lactulose and rifaximin.” NCT01773538 ↗ |
| Modality | Other / unclassified | “Dietary Supplement: branched-chain amino acids (BCAA) supplementation” NCT01687361 ↗ |
| Route | Oral | “Branched-chain aminoacids will be orally administered in the form of capsules” NCT01115686 ↗ |